3/26/2026 3:58:33 PM Competition litigation: 'user damages' for the unlawful collection and use of data? By Matthew Hunt The cause of action in competition cases in the UK is usually the tort of breach of statutory duty. As a general rule, the damages to be...
3/26/2026 9:53:33 AM A bump in the road? US DOJ subjects automotive licensing negotiation group to antitrust scrutiny By Sophie Lawrance Edwin Bond The US Department of Justice is investigating car manufacturers for participating in a licensee negotiation group (LNG), MLex has...
3/24/2026 7:10:42 PM From AI pricing algorithms to public procurement: UK Competition and Markets Authority publishes its 2026–27 annual plan By Victoria Yuan James Batsford On 23 March, the UK Competition and Markets Authority (CMA) published its 2026-2027 Annual Plan (the Annual Plan): the first since the...
3/24/2026 2:09:36 PM Biotech Review of the Year Issue 13 - out now! By Charlie French Ellen Lambrix Aida Tohala Erik Müürsepp +1 more... Show less We’re pleased to share the 13th edition of our Biotech Review of the Year, bringing together practical legal, regulatory and commercial...
3/24/2026 1:48:17 PM Commercial disputes in the life sciences sector: the complexity of assessing loss By Wes Walker This article is part of our Biotech Review of the Year - Issue 13 publication. Commercial disputes involving life sciences businesses are...
3/24/2026 1:48:15 PM 2026: A year of clarity for the SPC Manufacturing Waiver Regulation? By Luke Norton This article is part of our Biotech Review of the Year - Issue 13 publication. Between 2024 and 2025, there were multiple cases across...
3/24/2026 1:48:12 PM Has biotech litigation entered a new era? By Katie Cambrook Amy Howlett This article is part of our Biotech Review of the Year - Issue 13 publication. 2025 was an important year for biotech patent litigation,...
3/24/2026 1:48:08 PM From factory to bedside: decentralised medicines manufacturing in the UK By Hugo Kent-Egan This article is part of our Biotech Review of the Year - Issue 13 publication. The stated aim of the UK’s regulator for medicines, the...
3/24/2026 1:48:04 PM Trial by name, trial by nature: how lack of data protection harmonisation is hindering European clinical trials By Marc Dautlich Kiran Sidhu This article is part of our Biotech Review of the Year - Issue 13 publication. Europe’s ability to leverage its world-leading academic...
3/24/2026 1:47:26 PM Proposal for a European Biotech Act: will the Commission’s proposal unlock the potential of the health biotech industry in the EU? By Xisca Borrás This article is part of our Biotech Review of the Year - Issue 13 publication. December of 2025 was an exciting month for the life...
3/24/2026 1:47:23 PM Competition authorities in Europe target ‘killer acquisitions’ – what biotech companies need to know By Sophie Lawrance Victoria Yuan This article is part of our Biotech Review of the Year - Issue 13 publication. Competition authorities are increasingly targeting...
3/24/2026 1:47:20 PM Budget 2025: the key tax measures supporting science and innovation By Julia Cockroft Tabitha Reed This article is part of our Biotech Review of the Year - Issue 13 publication. On 26 November 2025, Rachel Reeves delivered her...